EYSINS, Switzerland, April 3, 2025 /PRNewswire/ -- Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

As sequencing projects of microbial organisms are being completed, a large number of genes of potential biological and medical relevance are classified as 'unknown' because their unique sequence and ...

EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...

EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...

Detection of somatic low abundance mutations in early cancer development requires a discriminatory, specific, and high-throughput methodology. In this study we report specific, discriminatory ...

AliveDx, a company that develops in-vitro diagnostic solutions to help patients get diagnosed and treated faster, announces the receipt of IVDR-CE mark for its MosaiQ AiPlex CTDplus multiplex assay.

PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely DetectX, EnviroX, and QuantX SANTA CLARA, ...

Systemic autoimmune Rheumatic Diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, Systemic Sclerosis (also known as Scleroderma), Sjögren's syndrome, idiopathic inflammatory ...

All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...